| 摘要 |
Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.; |
| 主权项 |
1. A compound of Formula (I) or pharmaceutically acceptable salts thereof, wherein: Z is CH or N; W is CR3 or N; R1 is:
(i) C1-4alkyl substituted with zero to 4 Ra;(ii) C3-6 cycloalkyl substituted with zero to 2 Ra;(iii) —S(O)2(C1-3alkyl), —S(O)2(C1-2fluoroalkyl), or —C(O)(C1-4alkyl);(iv) phenyl or naphthalenyl substituted with zero to 4 Rb; or(v) 1- or 2-ring heteroaryl comprising at least nitrogen heteroatom, substituted with zero to 4 Rc; R2 is:
(i) H, F, Cl, —ORd, —NHRe, or —C(O)O(C1-4alkyl);(ii) C1-4alkyl substituted with zero to 4 Ra; or(iii) C3-6 cycloalkyl; R3 is:
(i) H, F, Cl, —CN, —ORd, —NHRe, —C(O)O(C1-4alkyl); or(ii) C1-4alkyl substituted with zero to 4 Ra; or R2 and R3 can be combined to form:
(i) a 5- to 6-membered aryl fused radical substituted with zero to 1 Ra; or(ii) a 5- to 6-membered heteroaryl fused radical comprising one heteroatom, wherein said heteroaryl fused radical is substituted with zero to 1 Ra; each Ra is independently F, Cl, —OH, —CN, C3-6cycloalkyl, C1-2fluoroalkyl, C1-2fluoroalkoxy, and/or phenyl substituted with zero to 4 Rb; each Rb is independently F, Cl, Br, —OH, —CN, C1-4alkyl, C3-6cycloalkyl, C1-2fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy, —NH2, —NH(CH3), —N(CH3)2, —C(O)OH, —S(O)2(C1-4alkyl), and/or —S(O)2NRfRf; each Rc is independently F, Cl, Br, —CN, —OH, C1-4alkyl, C3-6cycloalkyl, C1-2fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy, —NH2, —NH(CH3), and/or —N(CH3)2; Rd is C1-4alkyl substituted with zero to 4 Ra; each Re is independently H and/or C1-4alkyl substituted with zero to 4 Ra; and each Rf is independently H, C1-6alkyl, C3-6cycloalkyl, C1-4fluoroalkyl, and/or aryl. |
